RAC

1.27%

$1.55 race oncology ltd

Please do let us know if any well known personalities in this...

First 511 Last

Share
Profile

Follow
EDTD

450 Posts.

410

08/05/24

09:38

Post #: 73718153
Share

Originally posted by johndprent: ↑

@HeyLine

Responding here:

"Hi John, Are you trying to say a licensing deal before CPACs (+FTO) clinical validation? Why would anyone want Bis if it's a rubbish athracycline (Masons words) and not clinically validated? Would the Chinese just be happy to use it off preclinical data? Has anyone shared an example of what these deals could look like?"

Seems odd that you're asking this question, which is effectively; why would anyone invest in Zan before CPACS + FTO clinical validation? Why are you invested here if not a result of our preclinical, and perhaps the implications of our clinical data? Big Mas also said this regarding Sheba 2.0; "The fact that there were no clinically relevant cardiotoxic events and no patient developed ECG changes is unequivocal..."

I'm invested in Zan because I think the odds are overwhelmingly in my favour and I want to enjoy the upside between preclinical and clinical validation (which I think might even be contained within the Sheba 2.0 data).

In terms of a licensing deal, I've applied a 99% risked discount to the extrapolation of the Triangle report based on securing 10% of the Chinese and Japanese Anthracycline + CPACS TAM (not even the entirety of Asia), which could be in the ballpark of ~US$900m (+royalties) prior to clinical validation. I believe applying an extremely discounted model could still net RAC >US$100m for licensing in China and Japan (+royalties) prior to clinical validation. Raising $100m now and diluting SOI by ~50% when we don't need the cash to achieve clinical validation is just nonsensical.

There's a lot of talk re waiting ~12 months for CPACS clinical validation for any sort of SP rerate. I don't subscribe to this. I expect an IND and international expansion of the CPACS trial will drive a rerate in anticipation of any clinical validation (unless of course it magically arrives sooner).

Expand

Please do let us know if any well known personalities in this thread award thumbs up on this sort of speculation. Even if they claim it merely means the comment has been read. Icebergs and outsized commercial returns blah blah blah.

Last edited by EDTD: 08/05/24

RAC Price at posting: $1.22 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Bitcoin: Current State of Play & Where to Next | Swyftx

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Emerald & Azure score Digger & Dealer awards

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

There are more pages in this discussion • 395 more messages in this thread...

First 511 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.55		Change -0.020(1.27%)		Mkt cap ! $264.0M

Open	High	Low	Value	Volume
$1.59	$1.62	$1.51	$218.3K	138.7K

Buyers (Bids)

No.	Vol.	Price($)
1	95	$1.53

Sellers (Offers)

Price($)	Vol.	No.
$1.55	157	1

View Market Depth

No.	Vol.	Price($)
1	95	1.525
3	29100	1.500
1	353	1.470
2	3444	1.440
3	101000	1.420

Price($)	Vol.	No.
1.550	157	1
1.580	6715	2
1.600	2319	1
1.620	5327	1
1.630	1270	1

Last trade - 16.10pm 16/08/2024 (20 minute delay)

RAC (ASX) Chart

Please do let us know if any well known personalities in this...

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Bitcoin: Current State of Play & Where to Next | Swyftx

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Emerald & Azure score Digger & Dealer awards

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Please do let us know if any well known personalities in this...

Top Stories

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Bitcoin: Current State of Play & Where to Next | Swyftx

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Emerald & Azure score Digger & Dealer awards

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News